Afghanistan

Reimbursed Care Access

Under the current de facto authorities and Afghanistan's constrained health system, classical and novel psychedelic compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X and plant brews such as ayahuasca) have no authorized medical or reimbursed access outside of tightly controlled research contexts (which are effectively non‑existent in practice). Ketamine is widely recognized internationally as an essential anaesthetic and is used in Afghan clinical practice for anaesthesia, but there is no structured national reimbursement programme for psychedelic therapies or for branded esketamine; access is limited, fragmented, and highly dependent on humanitarian/NGO supply and private facility availability. [https://apnews.com/article/65d307ad0c0857fe93b92268106c6adf|AP News: Afghanistan methamphetamine report].